

BEST OF ESMO

An ESMO Licensed Event



13 - 14

DECEMBER, 2025 | MUMBAI, INDIA

VENUE: THE St. REGIS MUMBAI



PROGRAM SCHEDULE

Hosted by



DAY 1



13 December 2025 (Saturday)

SESSION HIGHLIGHTS

Imperial Room - Hall - 1

09:00 - 11:05	Scientific Session	Track: Metastatic Breast Cancer
11:30 - 13:40	Scientific Session	Track: Locally Advanced Breast Cancer
14:20 - 15:30	Scientific Session	Track: Early Lung Cancers
15:50 - 18:05	Scientific Session	Track: Lung Cancer - Advanced
18:05 - 20:20	Symposium	Special Symposium - Imperial Room

Pallazzio Room - Hall - 2

10:00 - 17:30	Focus Session 1	Surgical Oncology
---------------	-----------------	-------------------

Crown Room - Hall - 3

14:00 - 17:10	Focus Session 2	Pediatric Hematology Oncology
---------------	-----------------	-------------------------------

DAY 2



14 December 2025 (Sunday)

Gynaecology

SESSION HIGHLIGHTS

Imperial Room - Hall - 1		
09:00 - 10:20	Scientific Session	Track: Head & Neck Cancers
10:50 - 11:00	Award Presentation	Award Paper Presentation
11:20 - 13:35	Scientific Session	Track: Gastrointestinal
14:25 - 16:40	Scientific Session	Track: Genitourinary
16:40 - 17:55	Scientific Session	Track: Gynaecology

Pallazzo Room - Hall - 2		
09:30 - 16:00	Focus Session 3	Radiation Oncology

DAY 1



13 December 2025 (Saturday)

Imperial Room | Hall - 1

Session 01 | Metastatic Breast Cancer

09:00 - 9:10

INAUGURATION
10 MINS

Welcome Remarks, Conference Inauguration, & Industry Introductions

Chairperson: Dr. BK Smriti, Dr. SD Banavali

09:10 - 09:50	5 MINS	LBA16	Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2- aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the Phase III evERA BC trial Speaker: Dr. Mehek Trikha (MO)
	5 MINS	LBA20	Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i) Speaker: Dr. Roshini Pandey (MO)
	5 MINS	LBA21	Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitor therapy: Primary results from the randomised, phase 3 TROPION-Breast02 trial Speaker: Dr. Sandhya S L (MO)
	5 MINS	LBA18	Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): additional analyses of DESTINY-Breast09 in key subgroups of interest Speaker: Dr. Lovin Wilson (MO)
	5 MINS	LBA23	Sacituzumab tirumotecan (sac-TMT) vs investigator's choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): results from the randomized, multi-center phase 3 OptiTROP - Breast02 study Speaker: Dr. Nihanti Srinath (MO)
	5 MINS	LBA17	Gedatolisib (geda) + fulvestrant _ palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/_HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1 Speaker: Dr. Darshit K Shah (MO)
	5 MINS	485MO	Health-Related Quality of Life (HRQoL) from the PATINA Trial (AFT-38): Impact of Adding Palbociclib to HER2 and Endocrine Therapy (ET) after Induction in HR+/HER2+ Metastatic Breast Cancer (MBC) Speaker: Dr. Siddharth Turkar (MO)

09:50 - 10:10	INDUSTRY 20 MINS	Topic: Early Triple Negative Breast Cancers Industry: MSD Speaker: Dr. Adwaita Gore
10:10 - 10:30	INDUSTRY 20 MINS	Topic: Optimising Survival Outcomes in HER2 Positive MBC Industry: Astra Zeneca Speaker: Dr. Adwaita Gore
10:30 - 10:45	INVITED 15 MINS	Topic: My changing Experience in Metastatic Breast Cancer in the last three decades Speaker: Dr. Suresh Advani (MO)

Moderators: Jyoti Bajpai (MO)

10:45 - 11:05	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Boman Dhabhar (MO) Dr. Smruti BK (MO) Dr. Mehboob Basade (MO) Dr. Mandar Nadkarni (SO) Dr. Reshma Palep (SO) Dr. Rima Pathak (RO)
---------------	--------------------------------	--	--

Chairpersons: Dr. Suresh Advani (MO), Dr. MB Agarwal (MO)

11:05 - 11:30	KEYNOTE 25 MINS	Topic: TBD Speaker: Dr. B S Ajaikumar
---------------	--------------------	--

Session 02 | Local & Locally Advanced Breast Cancer | Main Hall

Chairperson: Dr. Vani Parmar (SO), Dr. Hemant Malhotra (MO)

11:30 - 11:45	INVITED TALK 15 MINS	Topics: Recent Advances in Locoregional Therapy and Future in Breast Cancer Speaker: Dr. Harit Chaturvedi (MO)
11:45 - 12:15	INDUSTRY 30 MINS	Industry Panel Discussion: CDK4/6i in high-risk HR+, HER2- EBC: Patient selection, treatment benefit and management of side effects Industry: Eli Lilly Moderator: Dr. Adwaita gore Panellist: Dr. Ashutosh Kothari, Dr. Mehboob Basade

12:15 - 12:40	5 MINS	291O	DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) Speaker: Dr. Pushpak Chirmade (MO)
	5 MINS	3208O	Parity and breastfeeding enhance breast resident CD8 ₊ T cell immunity and protect against breast cancer Speaker: Dr. Darshana Rane (MO)
	5 MINS	323MO	Efficacy of adjuvant anti-PD-L1 avelumab by tumor infiltrating lymphocytes (TILs) for high-risk triple negative breast cancer in the phase III A-BRAVE trial. Speaker: Dr. Preetam Kumar Jain (MO)
	5 MINS	LBA15	Low Dose Pembrolizumab in Addition to Neoadjuvant Anthracycline and Taxane in Triple Negative Breast Cancer: A Randomized Controlled Trial Speaker: Dr. Anuradha Mehta (TMH)

	5 MINS	LBA12	5-Year Follow-up Results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial Speaker: Dr. Roshini Pandey (MO)
--	--------	-------	--

12:40 - 13:00	INDUSTRY 20 MINS	Topic: Management of Early Breast Cancers Industry: Astra Zeneca Speaker: Dr. Sachin Trivedi	
---------------	---------------------	---	--

Moderators: Dr. Vinay Deshmane (SO)

13:00 - 13:20	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Vaibhav Choudhary (MO) Dr. Anbarasan Sekar (MO) Dr. Fahad Afzal (MO) Dr. Bhavisha Ghugare (SO) Dr. Shalaka Joshi (SO) Dr. Ranjeet Bajpai (RO)
---------------	--------------------------------	--	--

13:20 - 13:55	35 MINS	LUNCH BREAK	
---------------	---------	--------------------	--

Chairperson: Dr. Asha Kapadia (MO), Dr. Vani Parmar (SO)

13:55 - 14:20	KEYNOTE 25 MINS	Topic: Advances In The Treatment Of HER2 +VE LABC/MBC Speaker: Dr. Hemant Malhotra (MO)	
---------------	--------------------	--	--

Session 03 | Early Lung Cancers | Main Hall

Chairperson: Dr. George Karimundakal (SO)

14:20 - 14:35	INVITED TALK 15 MINS	Topics: Recent Advances in SRS / SBRT for Early Lung Cancers Speaker: Dr. Shankar Vangipuram (RO)	
14:35 - 14:55	INDUSTRY 20 MINS	Topic: The Evolving Role of Immunotherapy in the LOCALLY ADVANCED Cervical Cancer Industry: MSD Speaker: Dr. Tasneem Bharmal	

14:55 - 15:10	5 MINS	LBA65	Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study Speaker: Dr. Siddharth Turkar (MO)
	5 MINS	1787MO	Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC) Speaker: Dr. Pushpendra Hirapara (MO)
	5 MINS	LBA67	Perioperative Pembrolizumab in Early-Stage Non–Small-Cell Lung Cancer (NSCLC): 5-Year Follow-Up From KEYNOTE-671 Speaker: Dr. Jimmy Mirani (MO)

Moderators: Dr. Srinivas KG (MO)

15:10 - 15:30	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists <i>Dr. Niyati Shah (MO)</i> <i>Dr. Sameer Srirangwar (MO)</i> <i>Dr. Kshitij Domadia (MO)</i> <i>Dr. Vijaykumar M (SO)</i> <i>Dr. Gagan Saini (RO)</i> <i>Dr. Shankar Vangipuram (RO)</i>
15:30 - 15:50	INVITED TALK 20 MINS	Topic: Decision-making in Oncology today - is it easier? Speaker: Dr. Rajiv Bhatt (SO)	

Session 04 | Lung Cancer - Advanced | Main Hall

Chairperson: TBD

15:50 - 16:10	INDUSTRY 20 MINS	Topics: Serplulimab : Reinventing wheel of NSCLC Industry: Intas Pharma Speaker: TBD	
16:10 - 16:30	INDUSTRY 20 MINS	Topics: RET-Driven Cancers: Evolving Paradigms in Precision Oncology Industry: Eli Lilly Speaker: Dr. Anabarsan Sekar	
16:30 - 16:45	INVITED TALK 15 MINS	Topics: ADCs in NSCLC Speaker: Dr. Govind Babu (MO)	
16:45 - 17:05	INDUSTRY 20 MINS	Topics: Improving survival Outcomes in EGFRm Metastatic NSCLC Through Combination Therapies Industry: Astra Zeneca Speaker: Dr. Jehyan Dhabhar	
17:05 - 17:25	5 MINS	1845MO	Prospective observational study of brigatinib after alectinib in ALK-positive, non-small cell lung cancer: efficacy and biomarker analyses from Cohort A of the WJOG11919L/ABRAID trial Speaker: Dr. Nirmal Raut (MO)
	5 MINS	LBA77	FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi)_ platinum - pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC Speaker: Dr. Adwaita Gore (MO)
	5 MINS	LBA5	Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study Speaker: Dr Arvind Vaidyanathan (TMH)
	5 MINS	LBA74	Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1 Speaker: Dr. Dhvani Patel (MO)
17:25 - 17:45	INDUSTRY 20 MINS	Topic: Immuno-oncology in motion: Tislelizumab's promise in lung carcinoma Industry: Glenmark Speaker: Dr. Ganapathi Bhat	

Moderators: Dr. Rohit Pai (MO)			
17:45 - 18:05	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Rahul Chowdhary (MO) Dr. Harish Reddy (MO) Dr. Nirmal Raut (MO) Dr. Amit Chakraborty (SO) Dr. Anjana Sainani (MO) Dr. Kinjal Jani (RO) Dr. Trinanjan Basu (RO)

Session 5 | Special Symposium | Imperial Room

18:05 - 18:20	SYMPOSIUM 15 MINS	Topic: Evolving role of Biomarkers in Endometrial Cancer	Sponsor: GSK Speaker: Dr. Advaita Gore
18:20 - 18:50	SYMPOSIUM 30 MINS	Topic: Advancing Immuno-Oncology Through MMR Driven Insights in Endometrial Cancer	Sponsor: GSK Moderator: Dr. Vaibhav Chaudhary Panelists: Dr. Rohit Pai, Dr. Pushpak Chirmade, Dr. Viraj Nevrekar, Dr. Anbarasan Sekar, Dr. Rahul Chowdhary

18:50 - 20:20	90 MINS	Dinner
---------------	---------	--------

Surgical Oncology | Pallazio Room | Hall - 2

Parallel Session | Genito Urinary Malignancies

10:00 - 10:10	INAUGURATION 10 MINS	Welcome Remarks, Conference Inauguration
---------------	-------------------------	--

Chairperson: Dr. (Prof) Hemang Bakshi

10:10 - 10:40	15 MINS	1052P	Primary retroperitoneal lymphadenectomy (pRPLND) for clinical stage IIB seminomas – results from two high volume centres Speaker: Dr. Vipul Tilva
	15 MINS	2664EP	The Impact of Metastatectomy on survival rates in patients with Metastatic Clear Cell Renal Cell Carcinoma in the Era of Advanced Systemic Therapies: Insights from a Nationwide Registry Analysis. Speaker: Dr. Kapil Dev
	15 MINS	2678EP	The Role of Cytoreductive Nephrectomy in Improving Survival for Non-Clear Cell Metastatic RCC in the Era of Emerging Treatments: Analysis from National Cancer Database. Speaker: Dr. Vijaykumar M

Moderators: Dr. Shishir Shetty

10:40 - 11:10	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Mangesh Patil Dr. Vipul Tilva Dr. Kapil Dev Dr. Vijaykumar M Dr. Sanket Sathe
---------------	-----------------------------	---	---

11:10 - 11:20	INVITED TALK 10 MINS	<i>Topic: Tips and Tricks of Robotic IVC Thrombectomy in Renal Tumours</i> <i>Speaker: Dr. (Prof) Hemang Bakshi</i>
---------------	-------------------------	--

11:20 - 11:40	20 MINS	TEA BREAK
---------------	---------	-----------

Parallel Session | Head & Neck Malignancies

Chairperson: Dr. Richa Vaish

11:40 - 12:10	15 MINS	1453EP	Real-World Evidence on supportive care for surgical versus non-surgical patients with Locally Advanced Head and Neck Squamous Cell Carcinoma in Portugal - the TRACE2 study Speaker: Dr. Akash Tiwari
	15 MINS	1344P	A single-arm, phase II trial evaluating the efficiency and safety of neoadjuvant immunochemotherapy and radical surgery with reduced surgical extent in treating patients with locally advanced tongue squamous cell carcinoma Speaker: Dr. Satakshi Chatterjee
	15 MINS	3007EP	Is completion thyroidectomy necessary when five or more micrometastatic lymph nodes are detected after lobectomy in papillary thyroid carcinoma via transoral endoscopic vestibular approach (TOETVA)? Speaker: Dr. Nitin Bomanwar

Moderators: Dr. Prashanth Pawar

12:10 - 12:40	PANEL DISCUSSION 30 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	<i>Panelists</i> Dr. Richa Vaish Dr. Akash Tiwari Dr. Satakshi Chatterjee Dr. Nitin Bomanwar
---------------	-----------------------------	--	--

12:40 - 12:50	INVITED TALK 10 MINS	<i>Topic: Expert Comments</i> <i>Speaker: Dr. Prashant Pawar</i>
---------------	-------------------------	---

12:50 - 13:20	30 MINS	LUNCH BREAK
---------------	---------	-------------

Parallel Session | Breast Malignancies

Chairperson

13:20 - 14:05	7 MINS	411P	Evaluation of ICG-Guided Axillary Reverse Mapping in Breast Cancer Surgery: A Retrospective Observational Study Speaker: Dr. Niharika Garach
	7 MINS	611P	The incidence and prognosis of synchronous and metachronous peritoneal metastases in patients with breast cancer: A nationwide, population-based study Speaker: Dr. Imaan Rumani
	7 MINS	386P	The Innovative Lancet Technique for Breast-Conserving Oncoplastic Surgery in Small- to Medium-Sized Breasts with Tumors in the Lower Inner Quadrant: A Multicenter Retrospective Study (IOS Study) Speaker: Dr. Rijuta Aphale

13:20 - 14:05	7 MINS	385P	Is axillary intervention necessary for selected patients with cN0-1 breast cancer after neoadjuvant chemotherapy? Speaker: Dr. Nisha Hariharan
	7 MINS	403P	Axillary Lymph Node Dissection Offers No Survival Benefit in Breast Cancer Patients with Sentinel Lymph Node Micrometastases After Neoadjuvant Therapy Speaker: Dr. Sandeep Bipte
	7 MINS	404P	Impact of postmastectomy radiation therapy on complications in stage II–III breast cancer underwent mastectomy and breast reconstruction: A multicenter cohort study Speaker: Dr. Sumeet Shah

Moderators: Dr. Nisha Hariharan

14:05 - 14:25	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists Dr. Niharika Garach Dr. Imaan Rumani Dr. Rijuta Aphale Dr. Sandeep Bipte Dr. Sumeet Shah Dr. Amar Deshpande Dr. Elroy Saldanha
---------------	-----------------------------	--	---

14:25 - 14:35	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. Mehul Bhansali	
---------------	-------------------------	---	--

Parallel Session | Lung Malignancies

Chairperson

14:35 - 15:05	7 MINS	1805EP	Microwave Ablation Versus Lobectomy for Hilar Ground-Glass Opacity Nodules: A Single-Center Prospective Comparison of Oncologic Efficacy and Perioperative Outcomes Speaker: Dr. George Karimundakal
	7 MINS	1818MO	Surgery versus radiotherapy after induction therapy with serplulimab combined with chemotherapy for unresectable stage IIIB-IIIC non-small cell lung cancer: a randomized controlled, open-label, phase 2 trial Speaker: Dr. Tanveer Abdul Majeed
	7 MINS	2065EP	Thoracic Surgery vs Radiotherapy in TKI-Responsive Stage IV EGFR-Mutant adenocarcinoma: A Propensity-Matched National Database Analysis Speaker: Dr. Nikhil Rane
	7 MINS	2703P	Comparison of Open Thoractomy, Mini-open Thoracoscopically Assisted Thoracotomy, and Video-assisted Thoracoscopic Surgery in Pulmonary Metastatic Oseosarcoma: Result of 20-year Experience at Ruijin Hospital Speaker: Dr. Tejas Vispute

Moderators: Dr. George Karimundakal

15:05 - 15:25	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists Dr. Tanveer Abdul Majeed Dr. Nikhil Rane Dr. Tejas Vispute
---------------	-----------------------------	--	---

15:25 - 15:35	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. George Karimundakal	
15:35 - 15:55	20 MINS	TEA BREAK	
Parallel Session GI Malignancies			
Chairperson			
15:55 - 16:35	6 MINS	864EP	Clinical Features and Outcomes of Second Recurrence After Resection of Metachronous Recurrent Lesions in Colorectal Cancer Speaker: Dr. Vikas Bachelal Gupta
	6 MINS	868EP	Short/Long-Term Outcomes of Robotic-Assisted, Laparoscopic and Open Surgery for Locally Advanced Rectal Cancer Speaker: Dr. Pawan Sugoor
	6 MINS	745P	Estimating the clinical benefit of the secondary resection of metastases in liver-limited metastatic colorectal cancer: an individual patient data-based pooled analysis of nine randomized trials. Speaker: Dr. Ninad Katdare
	6 MINS	1469MO	Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): a multicenter, open-label, randomized phase III trial. Speaker: Dr. Jalaluddin Akbar
	6 MINS	1476P	Survival and healthcare pathways of patients following resection or ablation for hepatocellular carcinoma in France: the 'LIVERPOOL' nation-wide study Speaker: Dr. Soumil Vyas
	6 MINS	2096MO	Systemic Therapy, Gastrectomy and CRS/HIPEC vs Systemic Therapy Alone for Gastric Cancer with Limited Peritoneal Dissemination: Results of the Randomised PERISCOPE II Trial. Speaker: Dr. Amit Gupta
Moderators: Dr. Soumil Vyas			
16:35 - 16:55	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Biplab Mishra Dr. Tirathram Kaushik Dr. Vikas Bachelal Gupta Dr. Pawan Sugoor Dr. Ninad Katdare Dr. Jalaluddin Akbar Dr. Amit Gupta
16:55 - 17:25	INVITED TALK 30 MINS	Topic: The Impact of Technology in Medicine: A Timeless Trend ? Speaker: Dr. Raj Nagarkar	

Pediatric Hematology Oncology | Crown Room | Hall - 3

Session 1 - Paediatric Brain Tumour Session

Chairperson: Dr. Maya Prasad & Dr. Sripad Banavali

14:00 - 14:40	8 MINS	Update on the phase II study: to explore the efficacy and safety of luvometinib (FCN-159) in recurrent or progressive pediatric low-grade glioma with MAPK pathway-activated Speaker: Dr. Manam Mehra
	8 MINS	The impact of pubertal state on the onset and progression of pediatric low-grade gliomas: causal association or underlying biological mechanism? Speaker: Dr. Dhruti Pandya
	8 MINS	Recent advances in the management of pediatric high-grade gliomas Speaker: Dr. Shruti Mishra
	8 MINS	The Computational CAR: Using AI to Design Next-Generation Cellular Therapies Speaker: Dr. Gaurav Kharya (Online)
	8 MINS	CSF liquid biopsy as an Innovative Tool for Research on Patients with Leptomeningeal Metastasis and Pediatric Brain Tumors Speaker: Dr. Kumar Arghya
14:40 - 15:00	PANEL DISCUSSION 20 MINS	Moderator: Dr. Vikramjit Kanwar Panelists: Dr. Maya Prasad, Dr. Shweta Bansal, Dr. Tanveer Ahmed

Session 2 - Next Generation Diagnosis & Prognosis

Chairperson: Dr. Santanu Sen & Dr. Intezar Mehdi

15:00 - 15:40	10 MINS	Beyond the Microscope: Liquid Biopsies and MRD Detection in Pediatric Leukemias & Solid Tumors Speaker: Dr. Kiran Wankhad
	10 MINS	A transcriptomic model accurately predicting hematopoietic stem cell transplantation survival in pediatric acute myeloid leukemia Speaker: Dr. Aishwarya Wadia
	10 MINS	AI-based Prediction Model and Precise Risk Stratification in Pediatric Neuroblastoma Speaker: Dr. Nirali Sanghvi
	10 MINS	Next-generation Immunotherapy in Sarcomas (Ewing's & Osteosarcoma). Speaker: Dr. Anwasha
15:40 - 16:00	PANEL DISCUSSION 20 MINS	Moderator: Dr. Priti Mehta Panelists: Dr. Purva Kanvinde, Dr. Badira Parambil, Dr. Purvi

Session 3 - Next Generation Diagnosis & Prognosis

Chairperson: Dr. Santanu Sen & Dr. Intezar Mehdi

16:00 - 16:50	25 MINS	ESMO Award for Translational Research - Harnessing AI for precision oncology Speaker: Dr. Kriti Tripathi
	25 MINS	CD19/CD22 bispecific CAR-T cell therapy for relapsed/refractory large B-cell lymphoma: A prospective, single-arm, single-center, phase II clinical trial Speaker: Dr. Krunal Shah
16:50 - 17:10	PANEL DISCUSSION 20 MINS	Topic: Panel Discussion on Impact on India Practice based on above abstracts Moderator: Dr. Chintan Vyas Panelists: Dr. Chetan Dhamne, Dr. Santosh Asangi, Dr. Kriti Tripathi, Dr. Krunal Shah

DAY 2



14 December 2025 (Sunday)

Imperial Room | Hall - 1

Session 06 | Head and Neck Cancers | Main Hall

Chairperson: Dr. Jayesh Patel (SO), Dr. Prashant Pawar (SO)

09:00 - 09:20	INVITED 15 MINS	Topic: Management of Vascular Tumors of the Skull Base Speaker: Dr. Gaurav Medikeri (SO)
09:20 - 09:40	INDUSTRY 20 MINS	Topic: Role of IO and Its Sequencing Strategy in the Management of HNSCC Industry: MSD Speaker: Dr. Darshit Shah

09:40 - 10:00	5 MINS	1330MO	Neoadjuvant-adjuvant (neoadj-adj) pembrolizumab (pembro) plus standard-of-care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Participant-reported outcomes (PRO) in KEYNOTE-689 Speaker: Dr. Sandhya SL (MO)
	5 MINS	1317O	Results from CompARE phase III RCT: neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC) Speaker: Dr. Suhas Aagre (MO)
	5 MINS	1329MO	Enfortumab vedotin plus pembrolizumab (EV + P) as first-line (1L) treatment in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): results from a cohort of the EV-202 trial Speaker: Dr. Pushpendra Hirapara (MO)
	5 MINS	1319O	Neoadjuvant-adjuvant (neoadj-adj) pembrolizumab (pembro) plus standard-of-care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Participant-reported outcomes (PRO) in KEYNOTE-689 Speaker: Dr. Shivam Singla (MO)

Moderators: Dr. Amit Joshi (MO)

10:00 - 10:20	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Jeyhan Dhabar (MO) Dr. Rohit R Pai (MO) Dr. Khwaja Raziuddin (MO) Dr. Paresh P Naik (SO) Dr. Amit Chakraborty (SO) Dr. Mangesh Patil (SO) Dr. Bhavin Visariya (RO)
---------------	--------------------------------	--	---

Chairperson: Dr. Ramesh Bilimagga (RO)

10:20 - 10:50	KEYNOTE 30 MINS	Topic: Evolution of Management of early TNBC and insights from the TMH trial Speaker: Dr. Sudeep Gupta (SO)
---------------	--------------------	--

10:50 - 11:00	AWARD 10 MINS	Award Paper Presentation	
Session 07 Gastrointestinal Main Hall			
Chairperson: Dr. Govind Babu (MO), Dr. Avanish Saklani (SO)			
11:00 - 11:20	INDUSTRY 20 MINS	Topic: New Paradigm in management of Biliary Tract Cancer Industry: MSD Speaker: Dr. Pushpak Chirmade	
11:20 - 11:35	INVITED 15 MINS	Topic: Latest Advances in GI Cancers Speaker: Dr. Tejinder Singh (MO)	
11:35 - 11:55	INDUSTRY 20 MINS	Topic: Ivosidenib in Focus: Redefining the Cholangiocarcinoma Landscape Industry: Servier India Speaker: Dr. Sachin Trivedi	
11:55 - 12:15	5 MINS	LBA81	Event-free survival (EFS) with pathological outcomes in MATTERHORN: a randomised, Phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma Speaker: Dr. Sunit Lokwani (MO)
	5 MINS	729MO	Circulating tumor (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER Speaker: Dr. Manjeet Singh Ahlawat (MO)
	5 MINS	LBA29	Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): new results from CheckMate 8HW Speaker: Dr. Ritam Joardar (MO)
	5 MINS	LBA9	ctDNA-Guided Adjuvant Chemotherapy De-Escalation in Stage III Colon Cancer: Primary Analysis of the ctDNA-Negative Cohort from the Randomized AGITG DYNAMIC-III Trial (Intergroup Study of AGITG and CCTG) Speaker: Dr. Ruhi Kumar (MO)
12:15 - 12:35	INDUSTRY 20 MINS	Topic: Redefining Peri-Operative Care in Resectable GC & GEJC Industry: Astra Zeneca Speaker: Dr. Vaibhav Choudhary	
Moderators: Dr. Viraj Lavingia (MO)			
12:35 - 12:55	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Harish Reddy (MO) Dr. Sunit Lokwani (MO) Dr. Syed Monawer Karim (MO) Dr. Kapil Dev (SO) Dr. Prashanth Vanzar (SO) Dr. Vaibhav Sonawane (RO)
12:55 - 13:15	20 MINS	LUNCH BREAK	

Chairperson: Dr. Raj Nagarkar (SO)

13:15 - 13:45	KEYNOTE 30 MINS	<i>Topic: Advanced surgical management of Head and Neck Cancers</i> <i>Speaker: Dr. Arvind Krishnamurthy (SO)</i>
---------------	--------------------	--

Session 08 | Genitourinary | Main Hall

Chairperson: Dr. Mangesh Patil (SO), Dr. Hemang Bakshi (SO)

13:45 - 14:00	INVITED TALK 15 MINS	<i>Topics: Advances in GU Cancers</i> <i>Speaker: Dr. Anitha Ramesh (MO)</i>	
14:00 - 14:20	INDUSTRY 20 MINS	<i>Industry: Paradigm shift in the management of NMIBC</i> <i>Industry: Astra Zeneca</i> <i>Speaker: Dr. TB Yuvaraja</i>	
14:20 - 14:40	5 MINS	LBA95	Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESICIO trial <i>Speaker: Dr. Devendra Pal (MO)</i>
	5 MINS	2383O	A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPitello-281 <i>Speaker: Dr. Anokhi Shah (MO)</i>
	5 MINS	LBA8	IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer <i>Speaker: Dr. Pritam Kataria (MO)</i>
	5 MINS	LBA92	3-Weekly Docetaxel 75 mg/m2 vs 2-Weekly Docetaxel 50 mg/m2 in Combination with Darolutamide + ADT in Patients with mHSPC – Results from the Randomised Phase 3 ARASAFE Trial <i>Speaker: Dr. Sandeep Gadela (MO)</i>
14:40 - 15:00	INDUSTRY 20 MINS	<i>Topic: Shaping the future of mHSPC management with ARANOTE Launch</i> <i>Industry: Bayer</i> <i>Speaker: Dr. Rohit Pai</i>	
15:00 - 15:20	INDUSTRY 20 MINS	<i>Topic: Enfortumab Vedotin in relapsed / refractory bladder cancer</i> <i>Industry: Astella's Pharma</i> <i>Speaker: Dr. Sachin Trivedi</i>	
15:20 - 15:40	INDUSTRY 20 MINS	<i>Topic: Redefining Treatment Outcomes with Adjuvant Immunotherapy in Renal Cell Carcinoma</i> <i>Industry: MSD</i> <i>Speaker: Dr. Vaibhav Choudhary (MO)</i>	

Moderators: Dr. Indoo Ambulkar (MO)

15:40 - 16:00	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	<i>Panelists</i> <i>Dr. Rahul Chowdhary</i> <i>Dr. Aditya Dhanawat</i> <i>Dr. Jes Raphael</i> <i>Dr. Hemang Bakshi</i> <i>Dr. Vipul Tilva</i> <i>Dr. Pranav C</i> <i>Dr. Deepanjali Patel</i>
---------------	--------------------------------	--	--

Session 09 | Gynaecology | Main Hall

Chairperson: Dr. Ninad Katdare (SO), Dr. V Kannan (RO), Dr. Sanchayan Mondal (MO)

16:00 - 16:15	INVITED TALK 15 MINS	Topics: Parp Inhibitors in Ovarian Cancer Speaker: Dr. Karan Sood (MO)	
16:15 - 16:35	5 MINS	1065MO	First-in-human study of AZD5335, a folate receptor α (FR α)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer Speaker: Dr. Mansi Sandip Shah (MO)
	5 MINS	LBA44	Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025 Speaker: Dr. Anokhi Shah (MO)
	5 MINS	LBA3	Pembrolizumab vs Placebo Plus Weekly Paclitaxel _ Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer: Results from the Randomized Double-Blind Phase 3 ENGOT-ov65/KEYNOTE-B96 Study Speaker: Dr. Athira Surendran (MO)
	5 MINS	LBA39	Final overall survival (OS) results from the randomized double-blind phase III AtTend/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer Speaker: Dr. Kasturi Baruah (MO)

Moderators: Dr. Anitha Ramesh (MO)

16:35 - 16:55	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Karan Sood Dr. Sanchayan Mandal Dr. Richa Bansal Dr. Durva Kurkure Dr. Ranjeet Bajpai Dr. Prachi Sawant Dr. Prashant Nyati
16:55 - 17:05	EXPERT COMMENT	Panel Discussion on Impact on India Practice based on above abstracts Speaker: Dr. Boman Dhabhar (MO)	
17:05 - 17:15	EXPERT COMMENT	Conference Summary & Student Awards Presentation Speaker: Dr. Suresh Babu (MO)	

Radiation Oncology | Pallazio Room | Hall - 2

Parallel Session | Breast Malignancies

Chairperson: Dr. Ramesh Bilimagga

09:30 - 09:50	5 MINS	389P	A Competing Risk Analysis Model to Explore the Impact of Postoperative Radiotherapy for Sentinel Lymph Node Micrometastases or ITCs in Female Breast Cancer Speaker: Dr. Durva Kurkure
	5 MINS	388P	Long-Term Outcomes of Intraoperative Radiotherapy (IORT) in Early Breast Cancer (eBC) Speaker: Dr. Shreya Kunder
	5 MINS	576P	Simultaneous integrated boost (sib) intensity-modulated radiotherapy for treatment of bone metastases: late analysis of a breast cancer cohort Speaker: Dr. Shwetha Mutha
	5 MINS	342P	Decoding Male Breast Cancer: A Molecular Perspective on Diagnosis and Treatment Speaker: Dr. Revathy

Moderators: Dr. Tabassum W

09:50 - 10:10	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists <i>Dr. Manish Chandra Dr. Deepak Dangwal Dr. Sanjay MH, Pune Dr. Amrita S Dr. Namrata Bhagat</i>
10:10 - 10:20	INVITED TALK 10 MINS	<i>Topic: Expert Comments Speaker: Dr. Sumit Basu</i>	

Parallel Session | Head & Neck Malignancies

Chairperson: Dr. Shyam K Shrivastava

10:20 - 10:50	5 MINS	1320O	Postoperative adjuvant radiochemotherapy with cisplatin (aRCH) vs. aRCH plus pembrolizumab in locally advanced head and neck squamous cell carcinoma (HNSCC): First data of the ADRISK trial Speaker: Dr. Koustav Majumdar
	5 MINS	1321O	Concurrent Chemoradiotherapy with/without Adjuvant Capecitabine in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Controlled Phase III Trial Speaker: Dr. Shwetabh Sinha
	5 MINS	1322O	A phase III randomized trial of prophylactic radiation with 2-step40 versus SIB56 IMRT techniques for locally advanced squamous cell carcinoma of the head and neck (JCOG1912, NEW BRIDGE) Speaker: Dr. Anuj Kumar
	5 MINS	1328MO	Hypofractionated radiotherapy of single tumor lesion increases systemic response rate to pembrolizumab in recurrent or metastatic head and neck cancer (R/M-HNSCC): Primary endpoint of the randomized Keynote-717 trial Speaker: Dr. Pooja N Patel

	5 MINS	1332P	A phase II study of SBRT followed by neoadjuvant chemo immunotherapy of Sintilimab plus docetaxel and cisplatin for in locoregionally advanced squamous cell carcinoma of oral cavity and oropharynx Speaker: Dr. Samir Batham
	5 MINS	1467E	Neoadjuvant SBRT sequential Tislelizumab in locally advanced head and neck squamous cell carcinoma: A single-arm, phase II trial (NEOSTART study). Speaker: Dr. Ritika Hinduja

Moderators: Dr. Gagan Saini

10:50 - 11:10	PANEL DISCUSSION 20 MINS	Panel Discussion on Impact on India Practice based on above abstracts	Panelists Dr. Riddhi J Talukdar Dr. Rohit Malde Dr. Samarpita Dr. Renjeet Bajpai Dr. HIRAK Vyas, Ahmedabad Dr. Sharbani G Laskar Dr. Ashwini Budrukar
11:10 - 11:20	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. Sarbani G Laskar	
11:20 - 11:30	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. Ashwini Budrukar	

Parallel Session | Lung Malignancies

Chairperson: Dr. Nagraj Huligol

11:30 - 12:05	4 MINS	1786O	External validation of AI for early-stage lung cancer recurrence prognosis using CT radiomics Speaker: Dr. Guncha Maheshwari
	4 MINS	2760MO	Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDEATE-Lung01 Speaker: Dr. Kinjal Jani
	4 MINS	1847MO	Activity of Ziplertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations Speaker: Dr. Mahesh Upasani
	4 MINS	1818MO	Surgery versus radiotherapy after induction therapy with serplulimab combined with chemotherapy for unresectable stage IIIB-IIIC non-small cell lung cancer: a randomized controlled, open-label, phase 2 trial Speaker: Dr. Bhavin Visariya
	4 MINS	LBA72	NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Speaker: Dr. Deep S Pruthi
	4 MINS	1797P	Clinical risk stratification for lung nodules: evidence from a non risk based lung cancer screening in a Chinese cohort Speaker: Dr. Roshan Patil
	4 MINS	1794P	Global quantitative assessment of multidisciplinary team (MDT) care in early-stage NSCLC Speaker: Dr. Unmesh M
	4 MINS	1795P	SMARCA4, c-MET and PD-L1 expression in pN2 non-small cell lung cancer from LungART IFCT 0503 trial. Speaker: Dr. Prashant Nayek

	4 MINS	1807EP	Prospective Cohort Study Comparing Characteristics and Outcomes of Octogenarians with Early-Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy or Surgery Speaker: Dr. Ramesh Purohit
--	--------	--------	---

Moderators: Dr. Kaustav Talapatra

12:05 - 12:25	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists Dr. Nikhil Kalyani Dr. Pranav C Dr. Madan Maitre Dr. Mangesh Patil Dr. Prasad Tanawade Dr. Manas Senapati
---------------	-----------------------------	--	--

12:25 - 12:35	INVITED TALK 10 MINS	<i>Topic: Expert Comments</i> Speaker: Dr. JP Agarwal
12:35 - 12:45	INVITED TALK 10 MINS	<i>Topic: Expert Comments</i> Speaker: Dr. Kaustav Talapatra

12:45 - 13:15	30 MINS	LUNCH BREAK
---------------	---------	-------------

Parallel Session | Genito Urinary Malignancies

Chairperson: Dr. Sharmila Agarwal

13:15 - 14:00	5 MINS	LBA89	A randomized phase 2 study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21 Speaker: Dr. Priyamvada
	5 MINS	2595MO	Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment Speaker: Dr. Jay Sahu
	5 MINS	2390P	Associations between quantitative baseline 68Ga-PSMA-11 PET parameters and 177Lu-PSMA-617 efficacy in the PSMAfore study Speaker: Dr. Nasim Shaikh
	5 MINS	2400P	Utilising the CHARTED and STAMPEDE2 criteria in the Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA PET) era: Implications on outcomes in metastatic prostate cancer (mPC) Speaker: Dr. Saurabha Kumar
	5 MINS	2386P	A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial Speaker: Dr. Pranav C
	5 MINS	2391P	LuPARP: Phase 1 trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Speaker: Dr. Sandeep De
	5 MINS	2389P	Final analysis of patients treated with [177Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France. Speaker: Dr. Bhoosan Zade

	5 MINS	2392P	PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): a randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) Speaker: Dr. Jatin Bhatia
	5 MINS	2387P	177Lu-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE) Speaker: Dr. Parth Verma

Moderators: Dr. Trinanjan Basu

14:00 - 14:20	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists Dr. Priyamvada Dr. Bhoosan Zade, Pune Dr. Kinjal Jani Dr. Kaustav Talapatra Dr. Saurabha Kumar Dr. Gagan Saini, Delhi. Dr. Vaibhav Sonwani,
---------------	-----------------------------	--	--

14:20 - 14:30	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. V Kannan	
---------------	-------------------------	---	--

Parallel Session | Gynecological & GI Malignancies

Chairperson: Dr Manish Chandra

14:30 - 15:15	15 MINS	2231P	Modified FOLFIRINOX with or without stereotactic body radiation (SBRT) in patients with locally advanced pancreatic cancer (LAPC): Randomized phase 2 SABER trial Speaker: Dr. Shiv K Gudi
	15 MINS	1088P	Metastasis-directed stereotactic radiotherapy (mdSBRT) for patients (pts) with oligoprogressive, oligorecurrent or oligopersistent (oligo-pr/re/pe) high grade ovarian cancer (HGOC) Speaker: Dr. Prachi Sawant
	15 MINS	887EP	Optimal Timing of SBRT Combined with Immune Checkpoint Inhibitors in MSS Colorectal Liver Metastases: A Real-World Cohort Study with Immune Microenvironment Analysis Speaker: Dr. Shanu Jain

Moderators: Dr. Rahul K

15:15 - 15:35	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists Dr. Shreyasi Karmakar Dr. Sagar Gayakwad Dr. Vaibhav Sonwani Dr. Mayuresh Virkar Dr. Akshay Mangaj Dr. Maitri Gandhi
---------------	-----------------------------	--	---

15:35 - 16:00	INVITED TALK 25 MINS	Session Summary & Takeways Speaker: Dr. Shyam Srivastava, Dr. Ramesh Bilimagga	
---------------	-------------------------	---	--

BEST OF ESMO

An ESMO Licensed Event



Hosted by



CONTACT US



Mr. George | +91 9008993636

Mrs. Sudiptaa Mitra | +91 8904216862



esmoindia@globalhealthcareacademy.in



www.globaloncocommunity.com

